Atlas Trials

NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial

Clinical trial NCT06821997 · RECRUITING

Trial details

NCT number
NCT06821997
Sponsor
Roswell Park Cancer Institute
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Borderline Resectable Pancreatic Ductal Adenocarcinoma
Start date
2026-03-02
Primary completion
2027-03-01
Enrollment
20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.